이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma

2026년 9월 23일 업데이트: Children's Oncology Group

A Phase 1/2 Trial of Chemoradiotherapy With 5-Fluorouracil and Maintenance Chemotherapy for High-Risk Posterior Fossa Ependymoma

This phase I/II trial tests the safety, side effects best dose and how well giving fluorouracil and tretinoin along with standard of care radiation therapy works for the treatment of high risk posterior fossa ependymoma that has not spread to other parts of the body (localized). Fluorouracil is a type medication called an antimetabolite. It works by stopping cells from making DNA and it may kill tumor cells. Tretinoin, also called all-trans retinoic acid (ATRA), retinoic acid, and vitamin A acid is in a class of medications called retinoids. It is made in the body from vitamin A and helps cells to grow and develop, especially in the embryo. Laboratory made form of tretinoin works by slowing or stopping the growth of tumor cells. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Giving fluorouracil and tretinoin along with standard of care radiation therapy may be safe, tolerable and/or effective in treating patients with localized high risk posterior fossa ependymoma.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

PRIMARY OBJECTIVE:

I. To assess the safety of intravenous (IV) bolus fluorouracil (5-FU) in combination with standard-of-care radiation therapy and to determine the recommended phase 2 dose (RP2D) when administered concurrently with radiation therapy (RT) in children with newly-diagnosed localized high-risk posterior fossa type A (PFA) ependymoma. (Phase 1) II. To determine the safety of and RP2D for oral tretinoin (all trans retinoic acid [ATRA]) on an intermittent schedule in combination with bolus IV fluorouracil (5-FU) in children with newly-diagnosed localized high-risk PFA ependymoma as maintenance therapy after fluorouracil-based chemoradiotherapy. (Phase 1) III. To compare event-free survival (EFS) in children with newly-diagnosed high-risk PFA ependymoma treated with resection, radiation therapy (RT), fluorouracil (5-FU), and ATRA at the RP2D with historical controls from ACNS0831. (Phase 2)

SECONDARY OBJECTIVES:

I. To preliminarily define the antitumor activity of IV bolus fluorouracil (5-FU) in combination with standard-of-care radiation therapy and of oral tretinoin (ATRA) on an intermittent schedule in combination with bolus IV fluorouracil (5-FU) maintenance for pediatric patients with newly diagnosed localized high-risk PFA ependymoma within the confines of a Phase 1 study. (Phase 1) II. To estimate overall survival (OS) in children with newly-diagnosed high-risk PFA ependymoma treated with resection, RT, fluorouracil (5-FU), and oral tretinoin (ATRA) at the RP2D. (Phase 2)

EXPLORATORY OBJECTIVES:

I. To correlate presence of tumor cell free deoxyribonucleic acid (DNA) with methylation profiling and clinical outcome. (Phase 1/2) II. To correlate histopathologic grade, gene expression profiles, epigenetic profiles and chromosome copy number status with clinical outcome. (Phase 1/2) III. To bank tumor, blood and cerebrospinal fluid specimens for future studies and assessment of immune and molecular signatures that may predict response or resistance in high-risk PFA ependymoma. (Phase 1/2)

OUTLINE: This is a phase I, dose-escalation study of fluorouracil and tretinoin followed by a dose-expansion and phase II study.

CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy over 6 or 7 weeks. Starting on day 1, 2 or 3 of radiation, patients receive fluorouracil IV over 3-15 minutes on days 1 and 15, days 1, 8 and 15, or days 1, 8, 15 and 22 depending upon assigned dose level. Treatment is given in the absence of disease progression or unacceptable toxicity.

MAINTENANCE CHEMOTHERAPY: Four weeks after completion of chemoradiotherapy, patients receive fluorouracil IV on days 1, 8, 15 and 22 of each cycle and tretinoin orally (PO) three times daily (TID) on days 1-3, 8-10, 15-17 and 22-24 of each cycle. Cycles repeat every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo echocardiography or multigated acquisition (MUGA) scan, magnetic resonance imaging (MRI), lumbar puncture, and optional blood sample collection throughout the study.

After completion of study treatment, patients are followed up at relapse, every 4 months for years 1-3, then every 6 months for years 3-5.

연구 유형

중재적

등록 (추정된)

70

단계

  • 2 단계
  • 1단계

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

1년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • PRE-ENROLLMENT: Patients must be > 12 months and < 21 years of age at the time of enrollment

  • PRE-ENROLLMENT: Patient has newly diagnosed posterior fossa ependymoma based on institutional pathologic diagnosis

  • PRE-ENROLLMENT: The patient and/or their parents or legal guardians must have signed informed consent for APEC14B1 Part A - Eligibility Screening

  • PRE-ENROLLMENT: If relying on APEC14B1-MCI for molecular characterization, required specimens for molecular characterization should be submitted as soon as possible, preferably within 5 calendar days of definitive surgery

  • Patients must be > 12 months and < 21 years at the time of study enrollment

  • Patients must be newly diagnosed, localized and have eligibility confirmed by central review of molecular reports

  • Histologically confirmed diagnosis of Posterior fossa ependymoma, group PFA

  • Molecular high risk features including Chromosome 1q gain and/or chromosome 6q loss

  • Patients must be enrolled on study within 56 days of definitive surgical resection. If applicable, the day of subsequent resection to remove residual tumor will be regarded as the day of definitive surgery and must be within a month (31 days) of the initial resection

  • Patients must have negative lumbar CSF cytology.

    • Note: CSF cytology for staging should be performed no sooner than 14 days post operatively to avoid false positive CSF. Ideally, CSF should be obtained between Day 14 and Day 21 to allow for final staging status before enrollment onto the study. Patients with positive lumbar CSF cytology obtained 0 to 14 days after surgery should have lumbar cytology repeated to determine eligibility and final CSF status. Patients with negative CSF lumbar cytology from lumbar puncture obtained 0 to 14 days after surgery do not need cytology repeated. Patients with negative CSF cytology from lumbar puncture obtained prior to surgery do not need cytology repeated post-operatively.
    • CSF cytology does not need to be repeated if within 87 days prior to enrollment regardless of timing
  • Patients must have localized disease. Pre and post-operative whole brain MRI with and without gadolinium and spine MRI with gadolinium must be performed

    • Disease/staging imaging studies, including MRI brain (post operative) and spine (pre or post-operative), must be obtained within 31 days prior to enrollment and start of protocol therapy (repeat if necessary)
  • No prior treatment other than surgical intervention and corticosteroids. Patients are allowed to have had more than one surgical resection prior to enrollment. For patients who have subsequent surgery, the day of the subsequent resection to remove residual tumor will be regarded as the day of definitive surgery and must be within a month (31 days) of initial resection

  • Known HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • Peripheral absolute neutrophil count (ANC) ≥ 1000/ µL (performed within 7 days prior to enrollment)

  • Platelet count ≥ 100,000/µL (transfusion independent) (performed within 7 days prior to enrollment)

  • Hemoglobin ≥ 8 g/dL (may receive red blood cell [RBC] transfusions) (transfusion independent) (performed within 7 days prior to enrollment)

  • Adequate Renal Function Defined As:

    • A serum creatinine based on age/sex as follows (performed within 7 days prior to enrollment) OR

      • 1 to < 2 years: Maximum serum creatinine 0.6 mg/dL (male), 0.6 mg/dL (female)

      • 2 to < 6 years: Maximum serum creatinine 0.8 mg/dL (male), 0.8 mg/dL (female)

      • 6 to < 10 years: Maximum serum creatinine 1 mg/dL (male), 1 mg/dL (female)

      • 10 to < 13 years: Maximum serum creatinine 1.2 mg/dL (male), 1.2 mg/dL (female)

      • 13 to < 16 years: Maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)

      • >= 16 years: Maximum serum creatinine 1.7 mg/dL (male),1.4 mg/dL (female)

        • The threshold creatinine values in this Table were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Center for Disease Control (CDC)
    • a 24-hour urine Creatinine clearance ≥ 50 mL/min/1.73 m^2 (performed within 7 days prior to enrollment) OR

    • a GFR ≥ 50 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard) (performed within 7 days prior to enrollment)

      • Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable if using GFR for determine eligibility
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age (performed within 7 days prior to enrollment)

  • Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L* (performed within 7 days prior to enrollment)

    • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
  • Central nervous system function defined as:

    • Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.
    • Patients must not be in status epilepticus, a coma or assisted ventilation at the time of study enrollment
  • Adequate cardiac function

    • Shortening fraction of ≥ 27% by echocardiogram, or

    • Ejection fraction of ≥ 50% by echocardiogram, cardiac MRI, or radionuclide angiogram, AND

    • For Patients ≥ 18 years:

      • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
  • Test result showing no evidence of complete or partial absence of dihydropyrimidine dehydrogenase (DPYD) activity. This genetic test can be obtained at any time prior to enrollment at a College of American Pathology (CAP)/Clinical Laboratory Improvement Act (CLIA) certified laboratory. Patients with DPYD variants that result in complete or partial DPD deficiency are not permitted to enroll on this study

Exclusion Criteria:

  • Patients with metastatic disease by either MRI evaluation or lumbar CSF cytology are not eligible. Patients who are unable to undergo a lumbar puncture for assessment of CSF cytology are ineligible
  • Hypersensitivity to fluorouracil, tretinoin, other retinoids, or any component of the formulation
  • Personal history of Torsades de pointes, atrial fibrillation, supraventricular tachycardia (SVT), or heart failure; personal history of prolonged QT Syndrome; other uncontrolled arrhythmia in the past 6 months prior to study enrollment
  • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
  • Lactating females who plan to breastfeed their infants
  • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation. Patients who could become pregnant should use effective contraception during treatment and 1 month following the last dose of tretinoin or for 3 months following last dose of fluorouracil, whichever is longer. Patients with partners who could become pregnant should also use effective contraception during treatment and for 1 week after the last dose of tretinoin or 3 months after the last dose of fluorouracil, whichever is longer

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment (radiation, fluorouracil, tretinoin)

CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy over 6 or 7 weeks. Starting on day 1, 2 or 3 of radiation, patients receive fluorouracil IV over 3-15 minutes on days 1 and 15, days 1, 8 and 15, or days 1, 8, 15 and 22 depending upon assigned dose level. Treatment is given in the absence of disease progression or unacceptable toxicity.

MAINTENANCE CHEMOTHERAPY: Four weeks after completion of chemoradiotherapy, patients receive fluorouracil IV on days 1, 8, 15 and 22 of each cycle and tretinoin PO TID on days 1-3, 8-10, 15-17 and 22-24 of each cycle. Cycles repeat every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo echocardiography or MUGA, MRI, lumbar puncture, and optional blood sample collection throughout the study.

Given IV

다른 이름들:
  • 5-플루라실
  • 플루라실
  • 5 플루오로우라실
  • 5 플루오로우라실룸
  • 5푸
  • 5-플루오로-2,4(1H,3H)-피리미딘디온
  • 5-플루오로우라실
  • 5-푸
  • 5FU
  • AccuSite
  • 카라크
  • 플루오로 우라실
  • 플루우라실
  • 플루라블라스틴
  • 플루라세딜
  • 플루릴
  • 플루로블라스틴
  • 리보플루오르
  • 로 2-9757호
  • Ro-2-9757

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Undergo lumbar puncture

다른 이름들:
  • LP
  • 척추 천자

Undergo MUGA scan

다른 이름들:
  • 혈액 풀 스캔
  • 평형 방사성핵종 혈관조영술
  • 게이티드 혈액 풀 이미징
  • 무가
  • 방사성핵종 뇌실조영술
  • RNVG
  • SYMA 스캐닝
  • 동기화된 다중 게이트 수집 스캐닝
  • 무가 스캔
  • 다중 게이트 획득 스캔
  • 방사성핵종 뇌실도 스캔
  • 게이트 하트 풀 스캔
  • RNV 스캔

Undergo echocardiography

다른 이름들:
  • 심초음파
  • EC

Undergo blood and CSF sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Undergo standard of care radiation therapy

다른 이름들:
  • 암 방사선 요법
  • ENERGY_TYPE
  • 비추다
  • 조사
  • 방사능
  • 방사선 요법, NOS
  • 방사선 요법
  • RT
  • 치료, 방사선
  • 에너지 종류

Given PO

다른 이름들:
  • 베사노이드
  • 아트라
  • 레노바
  • 망막
  • 에어롤
  • 아비타
  • 스티바-A
  • 2,4,6,8-노나테트라엔산, 3,7-디메틸-9-(2,6,6-트리메틸-1-시클로헥센-1-일)-, (all-E)-
  • 아베렐
  • 아크노텐
  • 모든 트랜스-레티노산
  • 올트랜스 레티노산
  • 올 트랜스 비타민 A 산
  • 올트랜스-레티노익산
  • 모든 트랜스 비타민 A 산
  • 베타-레티노산
  • 코르데스 바스
  • 더마이롤
  • 에피-아베렐
  • 에우디나
  • 레틴에이 마이크로
  • 레틴에이마이크로
  • 레티노산
  • 레티솔-A
  • 로 5488
  • 스티바-A 포르테
  • 트랜스 레티노산
  • 트랜스 비타민 A 산
  • 트랜스-레티노산
  • 트레티노늄
  • 비타민 A 산
  • 비타민 A 산, 전 트랜스-
  • 비티노인

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Occurrence of dose limiting toxicity chemoradiotherapy (DLT) (phase 1)
기간: From the start of chemoradiotherapy until 4 weeks after completing chemoradiotherapy

Will report the sample proportion of analysis patients experiencing DLTs with binominal exact 95% confidence intervals by dose level. Other toxicity data will also be described as appropriate for supportive analyses.

From the start of chemoradiotherapy until 4 weeks after completing chemoradiotherapy
Occurrence of DLT for maintenance therapy (phase 1)
기간: From the start of the first maintenance therapy cycle until the end of the first maintenance therapy cycle (Cycle = 42 days)

Will report the sample proportion of analysis patients experiencing DLTs with binominal exact 95% confidence intervals by dose level. Other toxicity data will also be described as appropriate for supportive analyses. A planned supportive analysis will descriptively assess any interaction between increasing chemoradiotherapy dose and maintenance therapy tolerability.

From the start of the first maintenance therapy cycle until the end of the first maintenance therapy cycle (Cycle = 42 days)
Event free survival (EFS)
기간: From enrollment to the first of any of the following events: disease progression, disease recurrence, second malignant neoplasm, or death from any cause, up to 5 years

Will test whether the EFS in the prospective patients is superior to the historical control using a stratified log-rank test adjusting for resection status (subtotal resection [STR] or gross total resection/near total resection GTR/NTR]) with a one-sided type-1 error rate of 0.10. The primary analysis will also report the Kaplan-Meier estimates of the prospective and historical control patients. Planned supportive analyses will assess whether EFS differs by resection status within the prospective patients, and conduct separate resection status-specific comparisons between the prospective and corresponding historical control patients. These analyses will use unadjusted log-rank tests.

From enrollment to the first of any of the following events: disease progression, disease recurrence, second malignant neoplasm, or death from any cause, up to 5 years

2차 결과 측정

결과 측정
측정값 설명
기간
Overall response
기간: After completing chemoradiotherapy (up to 49 days) and after completing maintenance therapy (Up to 6 cycles (Cycle= 42 days))

STR patients will be analyzed separately from GTR/NTR patients, as GTR/NTR patients are only evaluable for experiencing progressive disease. Analyses will also be reported separately by dose level. We will report the response rates using the respective sample proportions and exact binomial two-sided 95% confidence intervals.

After completing chemoradiotherapy (up to 49 days) and after completing maintenance therapy (Up to 6 cycles (Cycle= 42 days))
Overall survival
기간: From enrollment to death from any cause, up to 5 years

Will be summarized by the Kaplan Meyer method with similar considerations for the analysis population and intercurrent events as for EFS.

From enrollment to death from any cause, up to 5 years

기타 결과 측정

결과 측정
측정값 설명
기간
Correlate presence of tumor cell free deoxyribonucleic acid (DNA) with methylation profiling and clinical outcome
기간: Up to 5 years

Will explore the associations between tumor cell free DNA and EFS using Cox models. Initial analyses will use univariable models, and suitable multivariable models will be considered, subject to data constraints (e.g., number of events).Cox models incorporating these covariates as baseline covariates will be used for covariates available at the time of enrollment, and landmark analyses or time-varying covariates will be used for analyses with post-enrollment covariates.

Up to 5 years
Correlate histopathologic grade with clinical outcome
기간: Up to 5 years

Will explore the associations between histopathologic grade and EFS using Cox models. Initial analyses will use univariable models, and suitable multivariable models will be considered, subject to data constraints (e.g., number of events).Cox models incorporating these covariates as baseline covariates will be used for covariates available at the time of enrollment, and landmark analyses or time-varying covariates will be used for analyses with post-enrollment covariates.

Up to 5 years
Correlate gene expression profiles with clinical outcome
기간: Up to 5 years

Will explore the associations between gene expression profiles and EFS using Cox models. Initial analyses will use univariable models, and suitable multivariable models will be considered, subject to data constraints (e.g., number of events).Cox models incorporating these covariates as baseline covariates will be used for covariates available at the time of enrollment, and landmark analyses or time-varying covariates will be used for analyses with post-enrollment covariates.

Up to 5 years
Correlate epigenetic profiles with clinical outcome
기간: Up to 5 years

Will explore the associations between epigenetic profiles and EFS using Cox models. Initial analyses will use univariable models, and suitable multivariable models will be considered, subject to data constraints (e.g., number of events).Cox models incorporating these covariates as baseline covariates will be used for covariates available at the time of enrollment, and landmark analyses or time-varying covariates will be used for analyses with post-enrollment covariates.

Up to 5 years
Correlate chromosome copy number status with clinical outcome
기간: Up to 5 years

Will explore the associations between chromosome copy number status and EFS using Cox models. Initial analyses will use univariable models, and suitable multivariable models will be considered, subject to data constraints (e.g., number of events).Cox models incorporating these covariates as baseline covariates will be used for covariates available at the time of enrollment, and landmark analyses or time-varying covariates will be used for analyses with post-enrollment covariates.

Up to 5 years
Bank tumor, blood and cerebrospinal fluid specimens for future studies and assessment of immune and molecular signatures
기간: Up to 5 years

The number of patients consenting to collect tumor, blood and cerebrospinal fluid specimens, along with the number of submitted specimens, will be recorded as a part of routine study monitoring.

Up to 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Adam J Esbenshade, Children's Oncology Group

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 11일

기본 완료 (추정된)

2037년 6월 30일

연구 완료 (추정된)

2037년 6월 30일

연구 등록 날짜

최초 제출

2026년 9월 18일

QC 기준을 충족하는 최초 제출

2026년 9월 23일

처음 게시됨 (실제)

2026년 9월 30일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 30일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 23일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • ACNS2422
  • U10CA180886 (미국 NIH 보조금/계약)
  • NCI-2026-06714 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • ACNS2422 (기타 식별자: Children's Oncology Group)
  • ACNS2422 (기타 식별자: CTEP)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .